Market Overview
The Biosimulation Market is experiencing robust growth as regulatory agencies increasingly accept model-informed drug development (MIDD) submissions to support dosing recommendations, label expansions, and pediatric trial waivers. The FDA, EMA, and PMDA have issued guidance documents encouraging the use of biosimulation to optimize trial design, reduce patient exposure to...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Tiếng Việt